So far, most clinical trials have focused on delivering classical clinical drugs, such as docetaxel/paclitaxel, or PD1 (programmed cell death 1), in combination with cancer-specific antigens (FixVac-PD1) to increase the immune response [38] (Table 4). Here, PDCD1 is linked to cancer.